Serrano Arnaldo L, Lomont Justin P, Tu Ling-Hsien, Raleigh Daniel P, Zanni Martin T
Department of Chemistry, University of Wisconsin-Madison , Madison, Wisconsin 53706, United States.
Department of Chemistry, Stony Brook University , Stony Brook, New York 11790, United States.
J Am Chem Soc. 2017 Nov 22;139(46):16748-16758. doi: 10.1021/jacs.7b08830. Epub 2017 Nov 7.
Transiently populated oligomers formed en route to amyloid fibrils may constitute the most toxic aggregates associated with many amyloid-associated diseases. Most nucleation theories used to describe amyloid aggregation predict low oligomer concentrations and do not take into account free energy costs that may be associated with structural rearrangements between the oligomer and fiber states. We have used isotope labeling and two-dimensional infrared spectroscopy to spectrally resolve an oligomeric intermediate during the aggregation of the human islet amyloid protein (hIAPP or amylin), the protein associated with type II diabetes. A structural rearrangement includes the FGAIL region of hIAPP, which starts from a random coil structure, evolves into ordered β-sheet oligomers containing at least 5 strands, and then partially disorders in the fibril structure. The supercritical concentration is measured to be between 150 and 250 μM, which is the thermodynamic parameter that sets the free energy of the oligomers. A 3-state kinetic model fits the experimental data, but only if it includes a concentration independent free energy barrier >3 kcal/mol that represents the free energy cost of refolding the oligomeric intermediate into the structure of the amyloid fibril; i.e., "oligomer activation" is required. The barrier creates a transition state in the free energy landscape that slows fibril formation and creates a stable population of oligomers during the lag phase, even at concentrations below the supercritical concentration. Largely missing in current kinetic models is a link between structure and kinetics. Our experiments and modeling provide evidence that protein structural rearrangements during aggregation impact the populations and kinetics of toxic oligomeric species.
在形成淀粉样纤维的过程中短暂形成的低聚物可能是与许多淀粉样相关疾病相关的最具毒性的聚集体。大多数用于描述淀粉样聚集的成核理论预测低聚物浓度较低,并且没有考虑到可能与低聚物和纤维状态之间的结构重排相关的自由能成本。我们使用同位素标记和二维红外光谱来光谱解析人胰岛淀粉样蛋白(hIAPP或胰淀素)聚集过程中的低聚物中间体,该蛋白与II型糖尿病相关。结构重排包括hIAPP的FGAIL区域,该区域从无规卷曲结构开始,演变成包含至少5条链的有序β-折叠低聚物,然后在纤维结构中部分无序。超临界浓度测量值在150至250μM之间,这是设定低聚物自由能的热力学参数。一个三态动力学模型符合实验数据,但前提是它包括一个大于3千卡/摩尔的与浓度无关的自由能垒,该自由能垒代表将低聚物中间体重新折叠成淀粉样纤维结构的自由能成本;即,需要“低聚物活化”。该能垒在自由能景观中创造了一个过渡态,减缓了纤维形成,并在滞后阶段产生了稳定的低聚物群体,即使在低于超临界浓度的情况下也是如此。当前动力学模型中很大程度上缺少结构与动力学之间的联系。我们的实验和建模提供了证据,证明聚集过程中的蛋白质结构重排会影响有毒低聚物物种的数量和动力学。